Dalton McLean, MD
Advanced Heart Failure and Transplant Cardiology · Greensboro, NCNPI 1316995400
Payments from drug & device makers
Across 1,175 payments — averaging $600.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$314K
- Cvrx, Inc.$242K
- Amgen$82K
- AstraZeneca$36K
- Merck$14K
- Abbott$2K
- plus $15K from 37 others
What the payments were for
- Food & beverage$21,88098%
- Education$4572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$815
- CARDIOMEMS$359
- Barostim Neo System$356
- Impella$243
- OPTIMIZER$229
- HeartMate 3 Left Ventricular Dev$181
- TRICLIP$150
- TherOx DS2 Console$147
- Catheter$147
- Downstream Cartridge$147
- HeartWare HVAD$139
- ONPATTRO$123
- AMVUTTRA$100
How this compares
$705,523 in reported general payments places this provider in the 90th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
See all advanced heart failure and transplant cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 184 | $4,938,430 |
| AmvuttraVutrisiran Sodium | 28 | $3,198,123 |
| UptraviSelexipag | 122 | $2,863,991 |
| OpsumitMacitentan | 189 | $2,383,702 |
| Tyvaso DpiTreprostinil | 64 | $1,556,100 |
| EntrestoSacubitril/Valsartan | 1,110 | $1,132,325 |
| AdempasRiociguat | 57 | $783,781 |
| FarxigaDapagliflozin Propanediol | 782 | $678,870 |
| EliquisApixaban | 776 | $661,445 |
| JardianceEmpagliflozin | 584 | $563,618 |
| VyndaqelTafamidis Meglumine | 18 | $376,621 |
| Repatha SureclickEvolocumab | 180 | $169,944 |
| XareltoRivaroxaban | 173 | $143,768 |
| Ambrisentan | 40 | $99,824 |
| VerquvoVericiguat | 100 | $86,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis, Vyndaqel | $355 | $5,976,496978 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,727 | $5,247,693311 claims |
| Alnylam Pharmaceuticals Inc.Amvuttra | $959 | $3,198,12328 claims |
| NovartisEntresto | $1,738 | $1,132,3251,110 claims |
| BayerAdempas, Kerendia | $838 | $794,70368 claims |
| AstraZenecaFarxiga, Brilinta | $36,342 | $715,320823 claims |
| Boehringer IngelheimJardiance | $1,083 | $563,618584 claims |
| Johnson & JohnsonXarelto | $1,215 | $143,768173 claims |
| Novo NordiskOzempic, Wegovy | $145 | $109,88799 claims |
| MerckVerquvo | $14,318 | $86,887100 claims |
| Lilly USA, LLCMounjaro | $14 | $66,13661 claims |
| AmgenCorlanor | $82,203 | $22,55534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
Other advanced heart failure and transplant cardiology in Greensboro
- Daniel BensimhonGreensboro$2.5M
- Benjamin StonerGreensboro$3K
- David IshizawarRaleigh$1.2M
- Stephen GreeneDurham$737K
- Emil MissovGreenville$582K
- Hassan AlhosainiWinston Salem$394K
- John RommelWilmington$394K
- Kishan ParikhRaleigh$318K
- Stephen ZouzoulasConcord$244K
- Benjamin TrichonAsheville$233K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.